Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MBX | Common Stock | Conversion of derivative security | +3.93M | 3.93M | Sep 16, 2024 | By Frazier Life Sciences X, L.P. | F1, F2 | |||
transaction | MBX | Common Stock | Purchase | $10M | +625K | +15.91% | $16.00 | 4.55M | Sep 16, 2024 | By Frazier Life Sciences X, L.P. | F2, F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MBX | Series A Convertible Preferred Stock | Conversion of derivative security | -18.9M | -100% | 0 | Sep 16, 2024 | Common Stock | 1.57M | By Frazier Life Sciences X, L.P. | F1, F2 | |||
transaction | MBX | Series B Convertible Preferred Stock | Conversion of derivative security | -28.3M | -100% | 0 | Sep 16, 2024 | Common Stock | 2.35M | By Frazier Life Sciences X, L.P. | F1, F2 |
Id | Content |
---|---|
F1 | Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. |
F2 | These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. |
F3 | Reflects shares purchased in the Issuer's initial public offering. |